A Phase 3b, Open-label, Multicenter, Two-Period, Slow-titration and Food Effect Study to Assess the Safety and Efficacy of KarXT in Participants With DSM-5 Schizophrenia

The purpose of this study is to assess the safety and efficacy of slowly increasing dose and food effect of KarXT in adult participants with schizophrenia.

开始日期2024-12-31

申办/合作机构

Karuna Therapeutics, Inc.

NCT06605950 / Recruiting临床1期

A 2-Part, Phase 1, Randomized, Double-blind, Placebo-controlled Study to Assess the Safety, Tolerability and Pharmacokinetics of Multiple Doses of Dual-burst Release of Xanomeline With Immediate-Release Trospium Chloride Versus KarXT in Healthy Adult and Elderly Participants of Japanese Ethnicity (Part 1) and an Open-label Study to Assess the Effect of Omeprazole on the Pharmacokinetics of Dual-burst Release of Xanomeline With Immediate-Release Trospium Chloride in Healthy Adult Participants (Part 2)

The purpose of this study is to assess the safety, tolerability, and pharmacokinetics (PK) of multiple doses of KarXT + KarX-EC capsules versus KarXT capsules in healthy adult and elderly participants of Japanese ethnicity and to assess the effect of multiple doses of omeprazole on the exposure of xanomeline and trospium administered as KarXT + KarX-EC capsules in healthy adult participants.

开始日期2024-10-01

申办/合作机构

Karuna Therapeutics, Inc.

NCT06585787 / Recruiting临床3期

A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Safety and Efficacy of KarXT for the Treatment of Psychosis Associated With Alzheimer's Disease

The purpose of this study is to evaluate the safety and efficacy of KarXT in adult participants with mild to severe Alzheimer's Disease (AD) with moderate to severe psychosis related to AD.

开始日期2024-09-26

申办/合作机构

Karuna Therapeutics, Inc.

100 项与曲司氯铵/呫诺美林相关的临床结果

登录后查看更多信息

100 项与曲司氯铵/呫诺美林相关的转化医学

登录后查看更多信息

100 项与曲司氯铵/呫诺美林相关的专利（医药）

登录后查看更多信息

项与曲司氯铵/呫诺美林相关的文献（医药）

2024-12-01·SCHIZOPHRENIA RESEARCH

Efficacy of KarXT on negative symptoms in acute schizophrenia: A post hoc analysis of pooled data from 3 trials

Article

作者: Kaul, Inder ; Targum, Steven D ; Horan, William P ; Miller, Andrew C. ; Brannan, Stephen K. ; Horan, William P. ; Targum, Steven D. ; Yohn, Samantha E. ; Yohn, Samantha E ; Claxton, Amy ; Marder, Stephen R ; Miller, Andrew C ; Marder, Stephen R. ; Brannan, Stephen K

BACKGROUND:

Currently approved antipsychotics do not adequately treat negative symptoms (NS), which are a major determinant of functional disability in schizophrenia. KarXT, an M₁ /M₄ preferring muscarinic receptor agonist, has shown efficacy as a broad-spectrum monotherapy for the treatment of schizophrenia in participants with acute psychosis. Post hoc analyses evaluated the possibility that NS improve independently of positive symptoms with KarXT in a subgroup of participants with moderate-to-severe NS and no predominance of positive symptoms.

METHODS:

Data were pooled from the three pivotal trials of KarXT monotherapy in people with schizophrenia with an acute exacerbation of psychosis. All 3 studies used similar 5-week randomized, double-blind, placebo-controlled designs (modified intention-to-treat sample N = 640). PANSS criteria proposed in the literature identified a subset of study participants (n = 64) with prominent NS.

RESULTS:

KarXT was significantly better than placebo on PANSS Marder Negative Factor Scores in the full sample (p < .001; Cohen's d = 0.42) and more so in the prominent NS subgroup (p < .001; Cohen's d = 1.18). Further, the KarXT effect in the NS subgroup remained significant after accounting for changes in positive symptoms, depression/anxiety, disorganization, and hostility.

CONCLUSIONS:

Participants with prominent NS revealed greater improvement of NS following KarXT therapy than the full sample that persisted after accounting for positive and other symptoms. While these findings must be interpreted with caution, they are consistent with the possibility that NS improvements associated with KarXT are not secondary to improvements in other symptom domains and support further investigation in larger, stable outpatient studies.

2024-12-01·SCHIZOPHRENIA RESEARCH

A network meta-analysis of KarXT and commonly used pharmacological interventions for schizophrenia

Article

作者: Wright, Abigail C ; McKenna, Avery ; Wright, Abigail C. ; Tice, Jeffrey A. ; Rind, David M ; Rind, David M. ; Agboola, Foluso ; Tice, Jeffrey A

BACKGROUND:

Dopaminergic antipsychotics for schizophrenia have modest effects on symptoms and can cause important side effects. KarXT is an investigational drug for schizophrenia with a novel mechanism targeting muscarinic receptors that may limit these side effects.

METHODS:

We conducted a systematic review and Bayesian random-effects network meta-analyses of short-term RCTs (3-8 weeks) that enrolled adults with schizophrenia. We compared KarXT to aripiprazole, risperidone, and olanzapine. We sought evidence for symptoms (Positive and Negative Symptoms Scale [PANSS]), weight gain, and all-cause discontinuation.

RESULTS:

We included 33 trials with 7193 participants. For total, positive, and negative symptoms, KarXT and the three antipsychotics were significantly more efficacious than placebo (mean difference [MD] vs placebo range for total symptoms: -10.67 to -8.05; positive symptoms: -3.46 to -2.53; negative symptoms: -1.99 to -1.44) but not significantly different from each other. KarXT was ranked as least likely to lead to weight gain. This was significant versus risperidone (-2.06 kg; 95 % CrI: -3.28, -0.87) and olanzapine (-2.86 kg; 95 % CrI: -3.97, -1.82). However, KarXT was ranked highest for all-cause discontinuation. This was significant versus risperidone (RR: 0.64; 95 % CrI: 0.46, 0.89) and olanzapine (RR: 0.6; 95 % CrI: 0.44, 0.83).

CONCLUSIONS:

KarXT and commonly used antipsychotics were more efficacious than placebo at reducing symptoms, but there were no clear differences in short-term efficacy among the active interventions. KarXT was less likely to cause weight gain, an important outcome for those with schizophrenia; short-term data do not permit evaluation of the risk for tardive dyskinesia. Long-term data are needed.

2024-10-01·CLINICAL THERAPEUTICS

Xanomeline and Trospium Chloride

作者: Beninger, Paul

426

项与曲司氯铵/呫诺美林相关的新闻（医药）

2024-11-11

·Endpoints

Crown jewel from AbbVie's Cerevel buyout fails two Phase 2 schizophrenia tests, Bristol Myers' stock soars

The centerpiece of AbbVie’s $8.7 billion Cerevel acquisition just imploded. Emraclidine, a schizophrenia program expected to compete with the newly-approved Cobenfy from Bristol Myers Squibb and Karuna, failed in two separate Phase 2 studies, AbbVie said Monday morning. There were no statistically significant differences between emraclidine and placebo on a schizophrenia assessment called PANSS across all dosing arms. The news prompted an earthquake on Wall Street, with AbbVie’s stock $ABBV down more than 12% at market open. Bristol Myers shares $BMY shot up as much as 13%, its highest one-day jump since March 2006, according to Bloomberg News . Cantor Fitzgerald analyst Olivia Brayer wrote the miss “wasn’t on anyone’s bingo card.” For Bristol Myers, it removes Cobenfy’s biggest competitor and may push peak sales estimates higher than the consensus of $4 billion. (BMS has not publicly said how much it expects in Cobenfy sales.) Emraclidine’s failure also could illustrate how the mechanism behind the drug, and newer neuroscience programs more broadly, is less of a slam dunk than investors might have thought. When Cobenfy, then known as KarXT, read out positively in Phase 3, biopharma companies flooded the space with money: Bristol Myers acquired Karuna for $14 billion and AbbVie bought Cerevel. Biotechs also raked in the cash. MapLight Therapeutics, which is developing a drug similar to Cobenfy, snagged a $225 million Series C last year. Neumora went public in September 2023 with a $250 million IPO. And Seaport Therapeutics, with much of the same leadership team that worked at Karuna, assembled a $225 million crossover round last month. But the failure serves as a reminder that CNS drug development remains starkly challenging, even for two drugs using similar mechanisms like emraclidine and Cobenfy. Stifel analyst Paul Matteis said in an investor note that the “easier” perception of making these drugs is partly due to recency bias, but also because of wins across neuro like in Alzheimer’s, epilepsy and depression. That is likely to change, he said: “The emraclidine failure today is likely to make investors incrementally more cautious on CNS ph2 studies (especially small ones) and the degree to which they firmly derisk a ph3.” Cobenfy is an M1/M4-preferring muscarinic agonist, while emraclidine is an M4 muscarinic receptor agonist. Matteis added that questions might emerge for companies with schizophrenia drugs targeting only M4, including Neumora $NMRA and Neurocrine Biosciences $NBIX . Those companies’ stock prices ticked up about 3% and 1.4% each. AbbVie executives previously described emraclidine as representing the “bulk of the value” of the Cerevel buyout. But it’s tough to see where that might come from, depending on how — or if — the company tries to bring it forward. In the first Phase 2 study, EMPOWER-1 randomized patients 1-to-1-to-1 across two dose levels (10 mg and 30 mg) and placebo. The second trial, EMPOWER-2, randomized patients the same way, but looked at 15 mg and 30 mg. All participants, regardless of dosing, took emraclidine once per day. Researchers measured the drug’s effect on PANSS out to six weeks. EMPOWER-1’s placebo group showed a PANSS decline of 13.5 points, compared to 14.7-point and 16.5-point declines in the 10 mg and 30 mg dosing arms, respectively. EMPOWER-2 demonstrated a 16.1-point decline in placebo patients, compared to 18.5-point and 14.2-point declines in the respective 15 mg and 30 mg dosing arms. AbbVie did not report any p-values for the differences, and executives declined an interview request through a company spokesperson. The spokesperson told Endpoints News that AbbVie is “continuing to analyze the data to determine next steps.” Matteis said a higher placebo effect than expected may have accounted for the failure, though “it’s outright surprising” to see both studies miss. He also noted that the 2-to-1 randomization of drug to placebo may have indicated to patients whether they were receiving the drug or not.

临床2期IPO临床结果并购临床失败

2024-11-11

·Firstwordpharma

Drug at centre of AbbVie's $8.7B deal for Cerevel fails in key schizophrenia studies

The crown jewel in AbbVie's $8.7-billion acquisition of Cerevel Therapeutics failed to live up to expectations in a pair of Phase II studies for schizophrenia, putting the future of the selective M4 muscarinic modulator, dubbed emraclidine, in doubt."While we are disappointed with the results, we are continuing to analyse the data to determine next steps," remarked Roopal Thakkar, chief scientific officer at AbbVie, whose shares slid 13% on Monday. By contrast, Bristol Myers Squibb's stock jumped by nearly the same amount. In September, the FDA's approval of Bristol Myers Squibb's Cobenfy (xanomeline / trospium chloride) to treat schizophrenia made it the first M1 and M4 muscarinic receptor dual agonist — the centrepiece of the company's $14-billion purchase of Karuna Therapeutics late last year — with a novel mechanism of action cleared for the disease in decades.High hopes dashedHopes had been high going into emraclidine's mid-stage readouts — which had been viewed as potentially registrational — partly due to a recent win for another drug that AbbVie gained through its Cerevel takeout. The selective D1/D5 dopamine receptor partial agonist tavapadon met the primary endpoint of the Phase III TEMPO-1 trial for early Parkinson's disease, adding to positive results in the TEMPO-3 study.Meanwhile, the EMPOWER-1 and -2 studies investigated emraclidine as a once-daily, oral monotherapy for adults with schizophrenia who are experiencing an acute exacerbation of psychotic symptoms. AbbVie said that both trials missed their main goal of showing a statistically significant reduction in change from baseline in the Positive and Negative Syndrome Scale (PANSS) total score compared to placebo at week six.Results from EMPOWER-1 showed that the mean reduction in PANSS was -14.7 for emraclidine 10 mg and -16.5 for the 30-mg dose, compared to -13.5 for placebo. In EMPOWER-2, the mean reduction in PANSS was -18.5 for emraclidine 15 mg and -14.2 for the 30-mg dose, versus -16.1 for placebo.Despite the apparent setback, AbbVie said neuroscience remains "a key area of focus" for the company.

临床3期临床结果并购临床2期上市批准

2024-11-11

·Pharmaceutical Technology

Investment surges, hurdles and emerging innovations in neuroscience

FT Global Pharma and Biotech Summit 2024. Credit: Irena Maragkou Innovation in neuropsychiatry has been dormant for nearly forty years, said Kabir Nath, CEO, Compass Pathways in a panel discussion at the FT Global Pharma and Biotech Summit on 7 November. Recent developments, such as the approval of Bristol Myers Squibb’s Cobenfy (xanomeline-trospium) for the treatment of schizophrenia and Sage Therapeutics’ approval of Zurzuave (zuranolone) in post-partum depression signify a change in that. The significant lack of innovation is changing, with large Phase III studies investigating psychedelics such as psylocibin in an effort to “move from anecdotal experience to evidence” Nath stated. Free Report How is the Biopharmaceutical industry evolving? 2021 was a year of continued innovation and change in the Biopharmaceutical industry. As the COVID-19 pandemic continues to take its toll on businesses worldwide, it’s time to look for new ways to create value, prepare for the future, and remain competitive in the ever-changing landscape. GlobalData’s expansive report examines the business environment and trends that shape the Biopharmaceutical industry. We highlight the most impactful emerging technologies, as well as the industry, regulatory, and macroeconomic factors that influence growth prospects. Access the report to: Benchmark the impact of major themes on the Biopharmaceutical industry. Gain a deeper "on the ground" perspective through exclusive opinions and analysis from industry respondents. Evaluate the effects of COVID-19 on the sector. Download the full report to understand what to expect and how to align your strategies for success. Thank you. You will receive an email shortly. Please check your inbox to download the Report. Go deeper with GlobalData Reports LOA and PTSR Model - CFTX-1554 in Fibrosis Reports LOA and PTSR Model - FT-003 in Wet (Neovascular / Exudative) Macula... Data Insights The gold standard of business intelligence. Find out more By GlobalData Submit Country Code * UK (+44) USA (+1) Algeria (+213) Andorra (+376) Angola (+244) Anguilla (+1264) Antigua & Barbuda (+1268) Argentina (+54) Armenia (+374) Aruba (+297) Australia (+61) Austria (+43) Azerbaijan (+994) Bahamas (+1242) Bahrain (+973) Bangladesh (+880) Barbados (+1246) Belarus (+375) Belgium (+32) Belize (+501) Benin (+229) Bermuda (+1441) Bhutan (+975) Bolivia (+591) Bosnia Herzegovina (+387) Botswana (+267) Brazil (+55) Brunei (+673) Bulgaria (+359) Burkina Faso (+226) Burundi (+257) Cambodia (+855) Cameroon (+237) Canada (+1) Cape Verde Islands (+238) Cayman Islands (+1345) Central African Republic (+236) Chile (+56) China (+86) Colombia (+57) Comoros (+269) Congo (+242) Cook Islands (+682) Costa Rica (+506) Croatia (+385) Cuba (+53) Cyprus North (+90392) Cyprus South (+357) Czech Republic (+42) Denmark (+45) Djibouti (+253) Dominica (+1809) Dominican Republic (+1809) Ecuador (+593) Egypt (+20) El Salvador (+503) Equatorial Guinea (+240) Eritrea (+291) Estonia (+372) Ethiopia (+251) Falkland Islands (+500) Faroe Islands (+298) Fiji (+679) Finland (+358) France (+33) French Guiana (+594) French Polynesia (+689) Gabon (+241) Gambia (+220) Georgia (+7880) Germany (+49) Ghana (+233) Gibraltar (+350) Greece (+30) Greenland (+299) Grenada (+1473) Guadeloupe (+590) Guam (+671) Guatemala (+502) Guinea (+224) Guinea - Bissau (+245) Guyana (+592) Haiti (+509) Honduras (+504) Hong Kong (+852) Hungary (+36) Iceland (+354) India (+91) Indonesia (+62) Iran (+98) Iraq (+964) Ireland (+353) Israel (+972) Italy (+39) Jamaica (+1876) Japan (+81) Jordan (+962) Kazakhstan (+7) Kenya (+254) Kiribati (+686) Korea North (+850) Korea South (+82) Kuwait (+965) Kyrgyzstan (+996) Laos (+856) Latvia (+371) Lebanon (+961) Lesotho (+266) Liberia (+231) Libya (+218) Liechtenstein (+417) Lithuania (+370) Luxembourg (+352) Macao (+853) Macedonia (+389) Madagascar (+261) Malawi (+265) Malaysia (+60) Maldives (+960) Mali (+223) Malta (+356) Marshall Islands (+692) Martinique (+596) Mauritania (+222) Mayotte (+269) Mexico (+52) Micronesia (+691) Moldova (+373) Monaco (+377) Mongolia (+976) Montserrat (+1664) Morocco (+212) Mozambique (+258) Myanmar (+95) Namibia (+264) Nauru (+674) Nepal (+977) Netherlands (+31) New Caledonia (+687) New Zealand (+64) Nicaragua (+505) Niger (+227) Nigeria (+234) Niue (+683) Norfolk Islands (+672) Northern Marianas (+670) Norway (+47) Oman (+968) Palau (+680) Panama (+507) Papua New Guinea (+675) Paraguay (+595) Peru (+51) Philippines (+63) Poland (+48) Portugal (+351) Puerto Rico (+1787) Qatar (+974) Reunion (+262) Romania (+40) Russia (+7) Rwanda (+250) San Marino (+378) Sao Tome & Principe (+239) Saudi Arabia (+966) Senegal (+221) Serbia (+381) Seychelles (+248) Sierra Leone (+232) Singapore (+65) Slovak Republic (+421) Slovenia (+386) Solomon Islands (+677) Somalia (+252) South Africa (+27) Spain (+34) Sri Lanka (+94) St. Helena (+290) St. Kitts (+1869) St. Lucia (+1758) Sudan (+249) Suriname (+597) Swaziland (+268) Sweden (+46) Switzerland (+41) Syria (+963) Taiwan (+886) Tajikstan (+7) Thailand (+66) Togo (+228) Tonga (+676) Trinidad & Tobago (+1868) Tunisia (+216) Turkey (+90) Turkmenistan (+7) Turkmenistan (+993) Turks & Caicos Islands (+1649) Tuvalu (+688) Uganda (+256) Ukraine (+380) United Arab Emirates (+971) Uruguay (+598) Uzbekistan (+7) Vanuatu (+678) Vatican City (+379) Venezuela (+58) Vietnam (+84) Virgin Islands - British (+1284) Virgin Islands - US (+1340) Wallis & Futuna (+681) Yemen (North)(+969) Yemen (South)(+967) Zambia (+260) Zimbabwe (+263) Country * UK USA Afghanistan Åland Islands Albania Algeria American Samoa Andorra Angola Anguilla Antarctica Antigua and Barbuda Argentina Armenia Aruba Australia Austria Azerbaijan Bahamas Bahrain Bangladesh Barbados Belarus Belgium Belize Benin Bermuda Bhutan Bolivia Bonaire, Sint Eustatius and Saba Bosnia and Herzegovina Botswana Bouvet Island Brazil British Indian Ocean Territory Brunei Darussalam Bulgaria Burkina Faso Burundi Cambodia Cameroon Canada Cape Verde Cayman Islands Central African Republic Chad Chile China Christmas Island Cocos Islands Colombia Comoros Congo Democratic Republic of the Congo Cook Islands Costa Rica Côte d"Ivoire Croatia Cuba Curaçao Cyprus Czech Republic Denmark Djibouti Dominica Dominican Republic Ecuador Egypt El Salvador Equatorial Guinea Eritrea Estonia Ethiopia Falkland Islands Faroe Islands Fiji Finland France French Guiana French Polynesia French Southern Territories Gabon Gambia Georgia Germany Ghana Gibraltar Greece Greenland Grenada Guadeloupe Guam Guatemala Guernsey Guinea Guinea-Bissau Guyana Haiti Heard Island and McDonald Islands Holy See Honduras Hong Kong Hungary Iceland India Indonesia Iran Iraq Ireland Isle of Man Israel Italy Jamaica Japan Jersey Jordan Kazakhstan Kenya Kiribati North Korea South Korea Kuwait Kyrgyzstan Lao Latvia Lebanon Lesotho Liberia Libyan Arab Jamahiriya Liechtenstein Lithuania Luxembourg Macao Macedonia, The Former Yugoslav Republic of Madagascar Malawi Malaysia Maldives Mali Malta Marshall Islands Martinique Mauritania Mauritius Mayotte Mexico Micronesia Moldova Monaco Mongolia Montenegro Montserrat Morocco Mozambique Myanmar Namibia Nauru Nepal Netherlands New Caledonia New Zealand Nicaragua Niger Nigeria Niue Norfolk Island Northern Mariana Islands Norway Oman Pakistan Palau Palestinian Territory Panama Papua New Guinea Paraguay Peru Philippines Pitcairn Poland Portugal Puerto Rico Qatar Réunion Romania Russian Federation Rwanda Saint Helena, Ascension and Tristan da Cunha Saint Kitts and Nevis Saint Lucia Saint Pierre and Miquelon Saint Vincent and The Grenadines Samoa San Marino Sao Tome and Principe Saudi Arabia Senegal Serbia Seychelles Sierra Leone Singapore Slovakia Slovenia Solomon Islands Somalia South Africa South Georgia and The South Sandwich Islands Spain Sri Lanka Sudan Suriname Svalbard and Jan Mayen Swaziland Sweden Switzerland Syrian Arab Republic Taiwan Tajikistan Tanzania Thailand Timor-Leste Togo Tokelau Tonga Trinidad and Tobago Tunisia Turkey Turkmenistan Turks and Caicos Islands Tuvalu Uganda Ukraine United Arab Emirates US Minor Outlying Islands Uruguay Uzbekistan Vanuatu Venezuela Vietnam British Virgin Islands US Virgin Islands Wallis and Futuna Western Sahara Yemen Zambia Zimbabwe Kosovo By downloading this Report, you acknowledge that GlobalData may share your information with GlobalData and that your personal data will be used as described in their Privacy Policy Tick here to opt out of curated industry news, reports, and event updates Submit Visit our Privacy Policy for more information about our services, how GlobalData may use, process and share your personal data, including information on your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address. A major hurdle in the neuroscience field is that Phase III trials are costly and current animal models do not translate well for CNS disorders, which makes clinical research for neuropsychiatry and neurodegenerative diseases challenging. This makes the right patient selection strategy crucial. Targeting the right patient population While discussing if the pharmaceutical sector is going to see a return on investment (ROI) in this field, Seth Ettenburg, President and CEO, BlueRock Therapeutics, highlighted that investment in neuroscience is cyclical, with some excitement for emerging treatments. However, this is underlined by a lack of clear causality and biomarkers which makes cures more elusive compared to other fields. Bromley noted that approval of a product in this very complex field is challenging and the launch of Leqembi was a remarkable example of establishing proof of concept in neurodegenerative diseases. Introducing new treatments for conditions like Alzheimer’s Disease requires massive infrastructure, said Kylie Bromley, Vice President and Managing Director, UK & Ireland, Biogen. Biogen’s Aduhelm (aducanumab) was one of the first amyloid-targeting drugs to be approved for Alzheimer’s treatment wave, but it was pulled from the market earlier this year. Additionally, identifying the right patients is crucial, as only a small subset—around 2% of diagnosed Alzheimer’s patients—are suitable for current treatments, with early-stage patients showing the best response. Therefore, improving diagnosis will be key to tackling neurodegenerative disease and thus investment in less intrusive diagnosis methods, such as blood-based biomarkers will be crucial. Overall “infrastructure implementation will enable access to treatments” she concluded. According to the speakers, investment in neuroscience involves a high risk, cost and failure rate. While discussing the case of Leqembi, which saw less commercial success than analysts initially expected, Nath compared it to Johnson & Johnson’s Spravato, which took many years but is now becoming a blockbuster drug. Innovation in neurodegenerative diseases. The importance of biomarkers and technology (such as blood-based diagnostics, AI) offering new diagnostic tools, was highlighted by Bromley, who mentioned the software Novoic can use AI to identify patients earlier for clinical trials, streamlining the process. Technology is increasingly critical in early patient identification and trial recruitment, especially in identifying pre-symptomatic patients as research is looking earlier in the disease. According to her, AI and analytics advancements could improve diagnostic efficiency and foster a more targeted approach, crucial for treatments with narrow patient applicability. Is raising money in neuroscience becoming easier? In the case of neuropsychiatry, Nath stated that the space is a small community, but there is growing interest in the therapeutic potential of psychedelics for PTSD, depression, and anxiety, despite regulatory hurdles and mixed public perception. However, large-scale robust trials are essential, especially in a field that lacks robust biological markers, he added. The neuropsychiatry field faces persistent challenges due to the lack of biological biomarkers for conditions like depression, relying instead on broad diagnostic labels. According to Nath, a precision approach is not applicable in neuropsychiatry as companies fail to transition from Phase II to Phase III clinical trials, bringing up the example of Alto Neuroscience’s recent setback in a Phase IIb trial (NCT05712187). Nath believes that the potential for functional improvements and quality-of-life gains fuels optimism and investment. With one in nine people having a CNS disorder, there is an unmet need and untapped opportunity and Ettenbrugh said “opportunity in the space drives investment”. Free Report How is the Biopharmaceutical industry evolving? 2021 was a year of continued innovation and change in the Biopharmaceutical industry. As the COVID-19 pandemic continues to take its toll on businesses worldwide, it’s time to look for new ways to create value, prepare for the future, and remain competitive in the ever-changing landscape. GlobalData’s expansive report examines the business environment and trends that shape the Biopharmaceutical industry. We highlight the most impactful emerging technologies, as well as the industry, regulatory, and macroeconomic factors that influence growth prospects. Access the report to: Benchmark the impact of major themes on the Biopharmaceutical industry. Gain a deeper "on the ground" perspective through exclusive opinions and analysis from industry respondents. Evaluate the effects of COVID-19 on the sector. Download the full report to understand what to expect and how to align your strategies for success. Thank you. You will receive an email shortly. Please check your inbox to download the Report. By GlobalData Submit Country Code * UK (+44) USA (+1) Algeria (+213) Andorra (+376) Angola (+244) Anguilla (+1264) Antigua & Barbuda (+1268) Argentina (+54) Armenia (+374) Aruba (+297) Australia (+61) Austria (+43) Azerbaijan (+994) Bahamas (+1242) Bahrain (+973) Bangladesh (+880) Barbados (+1246) Belarus (+375) Belgium (+32) Belize (+501) Benin (+229) Bermuda (+1441) Bhutan (+975) Bolivia (+591) Bosnia Herzegovina (+387) Botswana (+267) Brazil (+55) Brunei (+673) Bulgaria (+359) Burkina Faso (+226) Burundi (+257) Cambodia (+855) Cameroon (+237) Canada (+1) Cape Verde Islands (+238) Cayman Islands (+1345) Central African Republic (+236) Chile (+56) China (+86) Colombia (+57) Comoros (+269) Congo (+242) Cook Islands (+682) Costa Rica (+506) Croatia (+385) Cuba (+53) Cyprus North (+90392) Cyprus South (+357) Czech Republic (+42) Denmark (+45) Djibouti (+253) Dominica (+1809) Dominican Republic (+1809) Ecuador (+593) Egypt (+20) El Salvador (+503) Equatorial Guinea (+240) Eritrea (+291) Estonia (+372) Ethiopia (+251) Falkland Islands (+500) Faroe Islands (+298) Fiji (+679) Finland (+358) France (+33) French Guiana (+594) French Polynesia (+689) Gabon (+241) Gambia (+220) Georgia (+7880) Germany (+49) Ghana (+233) Gibraltar (+350) Greece (+30) Greenland (+299) Grenada (+1473) Guadeloupe (+590) Guam (+671) Guatemala (+502) Guinea (+224) Guinea - Bissau (+245) Guyana (+592) Haiti (+509) Honduras (+504) Hong Kong (+852) Hungary (+36) Iceland (+354) India (+91) Indonesia (+62) Iran (+98) Iraq (+964) Ireland (+353) Israel (+972) Italy (+39) Jamaica (+1876) Japan (+81) Jordan (+962) Kazakhstan (+7) Kenya (+254) Kiribati (+686) Korea North (+850) Korea South (+82) Kuwait (+965) Kyrgyzstan (+996) Laos (+856) Latvia (+371) Lebanon (+961) Lesotho (+266) Liberia (+231) Libya (+218) Liechtenstein (+417) Lithuania (+370) Luxembourg (+352) Macao (+853) Macedonia (+389) Madagascar (+261) Malawi (+265) Malaysia (+60) Maldives (+960) Mali (+223) Malta (+356) Marshall Islands (+692) Martinique (+596) Mauritania (+222) Mayotte (+269) Mexico (+52) Micronesia (+691) Moldova (+373) Monaco (+377) Mongolia (+976) Montserrat (+1664) Morocco (+212) Mozambique (+258) Myanmar (+95) Namibia (+264) Nauru (+674) Nepal (+977) Netherlands (+31) New Caledonia (+687) New Zealand (+64) Nicaragua (+505) Niger (+227) Nigeria (+234) Niue (+683) Norfolk Islands (+672) Northern Marianas (+670) Norway (+47) Oman (+968) Palau (+680) Panama (+507) Papua New Guinea (+675) Paraguay (+595) Peru (+51) Philippines (+63) Poland (+48) Portugal (+351) Puerto Rico (+1787) Qatar (+974) Reunion (+262) Romania (+40) Russia (+7) Rwanda (+250) San Marino (+378) Sao Tome & Principe (+239) Saudi Arabia (+966) Senegal (+221) Serbia (+381) Seychelles (+248) Sierra Leone (+232) Singapore (+65) Slovak Republic (+421) Slovenia (+386) Solomon Islands (+677) Somalia (+252) South Africa (+27) Spain (+34) Sri Lanka (+94) St. Helena (+290) St. Kitts (+1869) St. Lucia (+1758) Sudan (+249) Suriname (+597) Swaziland (+268) Sweden (+46) Switzerland (+41) Syria (+963) Taiwan (+886) Tajikstan (+7) Thailand (+66) Togo (+228) Tonga (+676) Trinidad & Tobago (+1868) Tunisia (+216) Turkey (+90) Turkmenistan (+7) Turkmenistan (+993) Turks & Caicos Islands (+1649) Tuvalu (+688) Uganda (+256) Ukraine (+380) United Arab Emirates (+971) Uruguay (+598) Uzbekistan (+7) Vanuatu (+678) Vatican City (+379) Venezuela (+58) Vietnam (+84) Virgin Islands - British (+1284) Virgin Islands - US (+1340) Wallis & Futuna (+681) Yemen (North)(+969) Yemen (South)(+967) Zambia (+260) Zimbabwe (+263) Country * UK USA Afghanistan Åland Islands Albania Algeria American Samoa Andorra Angola Anguilla Antarctica Antigua and Barbuda Argentina Armenia Aruba Australia Austria Azerbaijan Bahamas Bahrain Bangladesh Barbados Belarus Belgium Belize Benin Bermuda Bhutan Bolivia Bonaire, Sint Eustatius and Saba Bosnia and Herzegovina Botswana Bouvet Island Brazil British Indian Ocean Territory Brunei Darussalam Bulgaria Burkina Faso Burundi Cambodia Cameroon Canada Cape Verde Cayman Islands Central African Republic Chad Chile China Christmas Island Cocos Islands Colombia Comoros Congo Democratic Republic of the Congo Cook Islands Costa Rica Côte d"Ivoire Croatia Cuba Curaçao Cyprus Czech Republic Denmark Djibouti Dominica Dominican Republic Ecuador Egypt El Salvador Equatorial Guinea Eritrea Estonia Ethiopia Falkland Islands Faroe Islands Fiji Finland France French Guiana French Polynesia French Southern Territories Gabon Gambia Georgia Germany Ghana Gibraltar Greece Greenland Grenada Guadeloupe Guam Guatemala Guernsey Guinea Guinea-Bissau Guyana Haiti Heard Island and McDonald Islands Holy See Honduras Hong Kong Hungary Iceland India Indonesia Iran Iraq Ireland Isle of Man Israel Italy Jamaica Japan Jersey Jordan Kazakhstan Kenya Kiribati North Korea South Korea Kuwait Kyrgyzstan Lao Latvia Lebanon Lesotho Liberia Libyan Arab Jamahiriya Liechtenstein Lithuania Luxembourg Macao Macedonia, The Former Yugoslav Republic of Madagascar Malawi Malaysia Maldives Mali Malta Marshall Islands Martinique Mauritania Mauritius Mayotte Mexico Micronesia Moldova Monaco Mongolia Montenegro Montserrat Morocco Mozambique Myanmar Namibia Nauru Nepal Netherlands New Caledonia New Zealand Nicaragua Niger Nigeria Niue Norfolk Island Northern Mariana Islands Norway Oman Pakistan Palau Palestinian Territory Panama Papua New Guinea Paraguay Peru Philippines Pitcairn Poland Portugal Puerto Rico Qatar Réunion Romania Russian Federation Rwanda Saint Helena, Ascension and Tristan da Cunha Saint Kitts and Nevis Saint Lucia Saint Pierre and Miquelon Saint Vincent and The Grenadines Samoa San Marino Sao Tome and Principe Saudi Arabia Senegal Serbia Seychelles Sierra Leone Singapore Slovakia Slovenia Solomon Islands Somalia South Africa South Georgia and The South Sandwich Islands Spain Sri Lanka Sudan Suriname Svalbard and Jan Mayen Swaziland Sweden Switzerland Syrian Arab Republic Taiwan Tajikistan Tanzania Thailand Timor-Leste Togo Tokelau Tonga Trinidad and Tobago Tunisia Turkey Turkmenistan Turks and Caicos Islands Tuvalu Uganda Ukraine United Arab Emirates US Minor Outlying Islands Uruguay Uzbekistan Vanuatu Venezuela Vietnam British Virgin Islands US Virgin Islands Wallis and Futuna Western Sahara Yemen Zambia Zimbabwe Kosovo By downloading this Report, you acknowledge that GlobalData may share your information with GlobalData and that your personal data will be used as described in their Privacy Policy Tick here to opt out of curated industry news, reports, and event updates Submit Visit our Privacy Policy for more information about our services, how GlobalData may use, process and share your personal data, including information on your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

临床2期临床3期上市批准

100 项与曲司氯铵/呫诺美林相关的药物交易

登录后查看更多信息

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
精神分裂症	美国	Bristol Myers Squibb Co.	2024-09-26

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
急性精神分裂症	临床3期	中国	再鼎医药（上海）有限公司	2023-05-29
急性精神分裂症	临床3期	中国	Karuna Therapeutics, Inc.	2023-05-29
阿尔茨海默症	临床3期	美国	Karuna Therapeutics, Inc.	2022-08-23
阿尔茨海默症	临床3期	保加利亚	Karuna Therapeutics, Inc.	2022-08-23
阿尔茨海默症	临床3期	克罗地亚	Karuna Therapeutics, Inc.	2022-08-23
阿尔茨海默症	临床3期	捷克	Karuna Therapeutics, Inc.	2022-08-23
阿尔茨海默症	临床3期	法国	Karuna Therapeutics, Inc.	2022-08-23
阿尔茨海默症	临床3期	德国	Karuna Therapeutics, Inc.	2022-08-23
阿尔茨海默症	临床3期	意大利	Karuna Therapeutics, Inc.	2022-08-23
阿尔茨海默症	临床3期	塞尔维亚	Karuna Therapeutics, Inc.	2022-08-23

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT04820309 (EMERGENT-5, Company_Website) 人工标引	临床3期	精神分裂症	566	COBENFY	獵襯鬱繭艱選鑰餘艱憲(襯壓餘網願獵願積鏇鏇) = 觸憲積遞齋蓋夢觸夢膚淵鬱鹹夢餘製蓋廠繭齋 (構鹹鬱鹹構範襯窪蓋願 ) 更多	积极	2024-10-31
NCT04659174 (EMERGENT-4, Company_Website) 人工标引	临床3期	精神分裂症	156	COBENFY	蓋簾顧壓構願繭鬱簾衊(淵憲艱壓廠艱觸憲憲選) = 淵範醖築簾衊餘衊顧鬱鹹衊鹹製範積襯衊顧願 (築廠膚艱淵憲齋鏇選鬱 )	积极	2024-10-31
				Placebo	-
NCT05919823 (ZL-2701-001, NEWS) 人工标引	临床3期	精神分裂症	202	KarXT	蓋廠網廠衊構蓋淵衊鹽(廠願鏇觸艱顧廠鏇製範) = 襯獵選衊淵膚築構鹹網鹹願簾網繭窪鬱積顧網 (鹽觸鏇憲簾襯遞憲夢鹹 ) 达到更多	积极	2024-10-29
				Placebo	蓋廠網廠衊構蓋淵衊鹽(廠願鏇觸艱顧廠鏇製範) = 餘獵艱鹹蓋襯積獵製構鹹願簾網繭窪鬱積顧網 (鹽觸鏇憲簾襯遞憲夢鹹 ) 达到更多
NCT04659174 (EMERGENT-4, CTgov)	临床3期	精神分裂症	152	KarXT (KarXT Arm A)	築齋網衊齋網鹽構鹽願(鬱鏇淵餘遞製鑰簾製築) = 鏇廠積選簾顧膚蓋壓餘構獵餘鏇簾膚顧積壓憲 (夢網觸餘築廠廠夢鏇憲, 淵遞構鑰鹹鑰窪蓋鬱願 ~ 艱築獵憲顧製鑰餘鏇製) 更多	-	2024-10-28
				Placebo+KarXT (KarXT Arm B)	築齋網衊齋網鹽構鹽願(鬱鏇淵餘遞製鑰簾製築) = 壓齋鬱襯顧醖夢艱窪鹽構獵餘鏇簾膚顧積壓憲 (夢網觸餘築廠廠夢鏇憲, 壓鹹鹹範艱鬱觸選蓋繭 ~ 鬱觸願製網範獵醖壓願) 更多
NCT04738123 (FDA_CDER) 人工标引	临床3期	精神分裂症	234	COBENFY	衊鏇鑰餘獵襯鏇膚獵鏇(遞願積憲衊鹽觸齋糧廠) = 鹽醖鬱窪糧齋範鬱網願範夢鬱襯壓觸廠廠壓築 (膚夢鑰顧餘網繭範觸壓, 1.6)	积极	2024-09-26
				Placebo	衊鏇鑰餘獵襯鏇膚獵鏇(遞願積憲衊鹽觸齋糧廠) = 衊窪觸積簾糧鬱積範蓋範夢鬱襯壓觸廠廠壓築 (膚夢鑰顧餘網繭範觸壓, 1.6)
NCT04659161 (FDA_CDER) 人工标引	临床3期	精神分裂症	236	COBENFY	衊壓醖壓積膚壓壓選膚(積夢觸蓋齋壓鬱膚膚餘) = 遞繭遞繭艱構憲願壓網憲範壓廠餘築網憲淵築 (憲憲壓鑰鏇齋網繭範顧, 1.7)	积极	2024-09-26
				Placebo	衊壓醖壓積膚壓壓選膚(積夢觸蓋齋壓鬱膚膚餘) = 窪鹽襯鹹鬱範淵淵觸選憲範壓廠餘築網憲淵築 (憲憲壓鑰鏇齋網繭範顧, 1.6)
NCT05643170 (PENNANT, CTgov)	临床3期	精神分裂症	4	Trospium Chloride Capsules	鹹積鏇憲鏇衊顧齋壓鑰(齋糧鏇選衊獵壓壓蓋淵) = 選淵簾襯網願艱窪繭夢鹽築獵獵鬱蓋蓋範廠蓋 (衊簾壓鹹鑰餘醖糧膚鑰, 醖願醖積膚構願獵廠鹹 ~ 壓鹽構膚鑰鏇網鏇觸網) 更多	-	2024-06-12
NCT04659174 \| NCT04820309 (EMERGENT-5, Corporate Publications) 人工标引	临床3期	精神分裂症	718	KarXT	鏇廠憲鏇憲觸鬱糧築製(鹽遞廠積鑰膚製獵膚衊) = 62% of participants reported at least one. The most common treatment-related adverse events (≥5%) were nausea, vomiting, constipation, dry mouth, dyspepsia, dizziness, hypertension, and diarrhea, of which nearly all were mild or moderate in severity and transient in nature. 構壓齋襯積餘範醖醖觸 (襯蓋糧齋鏇淵獵窪齋蓋 ) 更多	积极	2024-04-06
NCT04659174 (EMERGENT-4, Corporate Publications) 人工标引	临床3期	精神分裂症	110	KarXT	齋願鹽糧餘艱鹹艱獵衊(鏇網餘襯淵壓夢製夢鹹) = 積構繭簾糧積積觸築築糧蓋鏇選鑰鏇壓鬱醖獵 (顧蓋鑰構選選鹹範鏇築 ) 更多	积极	2024-04-06
EMERGENT-3 (NEWS) 人工标引	临床阶段不明	精神分裂症	314	KarXT (EMERGENT-1)	繭憲鑰鬱構艱壓繭築獵(壓簾餘選衊醖範範鏇鬱) = 鹽蓋壓繭選鹹齋糧鏇選鬱觸願壓顧鬱遞鬱範顧 (艱憲範糧醖醖淵範壓選 ) 更多	积极	2024-01-08
				placebo (EMERGENT-1)	繭憲鑰鬱構艱壓繭築獵(壓簾餘選衊醖範範鏇鬱) = 網範憲鏇鬱顧網獵齋衊鬱觸願壓顧鬱遞鬱範顧 (艱憲範糧醖醖淵範壓選 ) 更多